

Supplementary Table 3. Baseline characteristics of the patients who did not receive PCI or coronary artery bypass graft, or received failed PCI

Characteristic	Before propensity score weighting method		p value
	On-hours group (n = 98)	Off-hours group (n = 155)	
Male patients	55 (56.1)	86 (55.5)	0.921
Age, yr	74.78 ± 11.28	73.25 ± 12.07	0.317
Age ≥ 65 years	78 (79.6)	118 (76.1)	0.521
First medical contact			0.734
Emergency medical service	13 (13.3)	28 (18.1)	
No emergency medical service	85 (86.7)	127 (82.0)	
PCI-capable center	22 (22.4)	26 (16.8)	
PCI-incapable center	63 (64.3)	101 (65.2)	
Onset-to-door time ≥ 4 hours	66 (67.3)	89 (57.4)	0.114
Pulse pressure, mmHg	46.03 ± 20.07	46.54 ± 21.71	0.852
Pulse pressure ≥ 40 mmHg	64 (66.7)	113 (72.9)	0.292
Killip functional classification			0.268
Killip functional class III	68 (69.4)	97 (62.6)	
Killip functional class IV	30 (30.6)	58 (37.4)	
BMI, kg/m ²	22.22 ± 3.19	22.49 ± 3.17	0.535
BMI ≥ 25 kg/m ²	15 (17.6)	30 (23.1)	0.339
Previous history			
Hypertension	63 (64.3)	103 (66.5)	0.724
Diabetes mellitus	40 (40.8)	70 (45.2)	0.497
Dyslipidemia	8 (8.2)	9 (5.8)	0.466
Prior MI	20 (20.4)	22 (14.2)	0.196
Prior heart failure	6 (6.1)	10 (6.5)	0.917
Prior CVA	16 (16.7)	24 (15.7)	0.838
Smoking	37 (37.8)	58 (37.4)	0.957
Family history of CAD	2 (2.2)	4 (2.7)	1.000
LVEF, %	40.40 ± 14.66	41.12 ± 14.94	0.744
LVEF < 40%	36 (48.6)	54 (47.4)	0.864
STEMI diagnosis	34 (34.7)	51 (32.9)	0.769
Use of thrombolysis	0	3 (1.9)	0.285
Discharge medications			
Aspirin	91 (92.9)	149 (96.1)	0.251
P2Y12 inhibitor	87 (88.8)	143 (92.3)	0.348
Calcium channel blocker	16 (16.3)	18 (11.6)	0.284
Beta-blocker	54 (55.1)	70 (45.2)	0.123
ACE inhibitor or ARB	54 (55.1)	73 (47.1)	0.215
Statin	56 (57.1)	88 (56.8)	0.954

Values are presented as number (%) or mean ± standard deviation.

PCI, percutaneous coronary intervention; BMI, body mass index; MI, myocardial infarction; CVA, cerebrovascular accident; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation myocardial infarction; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.